Soleno Therapeutics (SLNO) Other Non-Current Liabilities (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Other Non-Current Liabilities of $1.4 million for Q1 2026, up 882.76% year-over-year from $145000.0 in Q1 2025, and up 171.43% quarter-over-quarter from $525000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Other Non-Current Liabilities for 14 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 882.76% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 882.76% YoY), while the FY2025 annual figure was $525000.0, down 96.45% from the prior year.
- Other Non-Current Liabilities improved to $1.4 million in Q1 2026 per SLNO's latest filing, from $525000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $14.8 million in Q4 2024 and bottomed at $145000.0 in Q1 2025.
- Historically, Other Non-Current Liabilities has averaged $7.9 million across 5 years, with a median of $9.3 million in 2022.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities slumped 98.79% — and 2026, when it soared 882.76%.
- Soleno Therapeutics' Other Non-Current Liabilities stood at $8.8 million in 2022, then jumped by 30.72% to $11.5 million in 2023, then advanced by 28.07% to $14.8 million in 2024, then sank by 96.45% to $525000.0 in 2025, then surged by 171.43% to $1.4 million in 2026.
- Business Quant data shows SLNO's Other Non-Current Liabilities at $1.4 million in Q1 2026, $525000.0 in Q4 2025, and $398000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.43 Mn |
| Dec 31, 2025 | 525,000.00 |
| Sep 30, 2025 | 398,000.00 |
| Jun 30, 2025 | 271,000.00 |
| Mar 31, 2025 | 145,000.00 |
| Dec 31, 2024 | 14.79 Mn |
| Sep 30, 2024 | 14.46 Mn |
| Jun 30, 2024 | 13.59 Mn |
| Mar 31, 2024 | 11.95 Mn |
| Dec 31, 2023 | 11.55 Mn |
| Sep 30, 2023 | 10.47 Mn |
| Jun 30, 2023 | 9.45 Mn |
| Mar 31, 2023 | 9.13 Mn |
| Dec 31, 2022 | 8.84 Mn |
| Sep 30, 2022 | 9.44 Mn |
| Jun 30, 2022 | 9.31 Mn |
| Mar 31, 2022 | 8.69 Mn |
| Dec 31, 2021 | 9.55 Mn |
| Sep 30, 2021 | 12.88 Mn |
| Jun 30, 2021 | 12.33 Mn |